Biocompatibles UK Ltd. is a UK-based organization that specializes in producing and distributing medical devices designed for implantation in patients. Established in 2001, the company is headquartered in Farnham and focuses on delivering high-quality products to healthcare providers and patients alike.

Tags

Other Diseases

Therapeutic radiopharmaceuticals

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Small molecule drug	1
Therapeutic radiopharmaceuticals	1

Drugs associated with Biocompatibles UK Ltd.

Yttrium 90

Target-

Mechanism

Ionising radiation emitters

Active Org.

Eckert & Ziegler Radiopharma GmbH [+2]

Originator Org.

CIS Bio International SA

Active Indication

Diagnostic agents

Inactive Indication

Neuroendocrine Tumors

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

EU [+3]

First Approval Date24 Mar 2003

Clinical Trials associated with Biocompatibles UK Ltd.

NCT05063565 / RecruitingPhase 2

An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)

The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.

Start Date03 Nov 2023

Sponsor / Collaborator

Boston Scientific Corp.

[+1]

CTR20211074 / RecruitingPhase 3

一项比较特钇菲尔TM (钇[90Y]玻璃微球系统)与传统经动脉化疗栓塞治疗中国不可手术的原发性肝癌患者人群安全性及有效性的多中心、前瞻性、开放标签的随机对照临床研究

[Translation] A multicenter, prospective, open-label, randomized controlled clinical study comparing the safety and efficacy of TetrifilTM (yttrium [90Y] glass microsphere system) with conventional transarterial chemoembolization in the treatment of inoperable primary liver cancer in Chinese patients

评价钇[90Y]玻璃微球系统用于治疗不可手术的原发性肝癌患者的有效性及安全性

[Translation]

To evaluate the efficacy and safety of yttrium [90Y] glass microsphere system in the treatment of patients with inoperable primary liver cancer

Start Date13 Sep 2021

Sponsor / Collaborator

Biocompatibles UK Ltd.

[+1]

NCT04701918 / RecruitingPhase 2IIT

A Multicenter, Single-Arm Open Label Phase II Trial of Cryoablation in Combination With Pembrolizumab or Avelumab in Patients With Metastatic Urothelial Carcinoma

This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread.

Start Date04 Jun 2021

Sponsor / Collaborator

The General Hospital Corp.

[+1]

100 Clinical Results associated with Biocompatibles UK Ltd.

0 Patents (Medical) associated with Biocompatibles UK Ltd.

112

Literatures (Medical) associated with Biocompatibles UK Ltd.

01 Sep 2022·Journal of Vascular and Interventional Radiology

Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies

Article

Author: Wilde, Paul E ; Cooper, Sarah ; Lewis, Andrew L ; Counsell, Nicholas ; Atkinson, David ; Raja, Jowad ; Meyer, Tim ; Hague, Julian ; Sharma, Ricky A ; Bandula, Steven ; Pollok, Joerg-Matthias ; Stuckey, Daniel J ; Clarkson, Matthew J ; Hartley, John A ; Jansen, Marnix ; Bascal, Zainab A ; Thin, May Zaw ; Lowe, Helen L ; Beaton, Laura ; Ryan, Samantha ; Znati, Sami A ; Munneke, Graham ; Davidson, Brian R ; Sharma, Dinesh ; Boucher, Eveline ; Chouhan, Manil ; Czuczman, Peter ; Forsyth, Sharon ; Tregidgo, Henry F J

PURPOSETo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.MATERIALS AND METHODSThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7-21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.RESULTSEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441-404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%-100%). There were no significant changes in perfusion imaging parameters after TACE.CONCLUSIONSBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies.

01 Feb 2022·The British Journal of RadiologyQ3 · MEDICINE

Radiopaque drug-eluting embolisation beads as fiducial markers for stereotactic liver radiotherapy

Q3 · MEDICINE

Article

Author: Bascal, Zainab A ; Daly, Mairead ; Beaton, Laura ; Cooper, Sarah ; Sharma, Ricky A ; Znati, Sami ; Wilde, Paul E ; Bandula, Steven ; Tregidgo, Henry FJ ; Stacey, Chris ; Hague, Julian ; Lewis, Andrew L ; Grimes, Helen ; Clarkson, Matthew J ; Moinuddin, Syed

Objective:To determine the feasibility of using radiopaque (RO) beads as direct tumour surrogates for image-guided radiotherapy (IGRT) in patients with liver tumours after transarterial chemoembolisation (TACE).Methods:A novel vandetanib-eluting RO bead was delivered via TACE as part of a first-in-human clinical trial in patients with either hepatocellular carcinoma or liver metastases from colorectal cancer. Following TACE, patients underwent simulated radiotherapy imaging with four-dimensional computed tomography (4D-CT) and cone-beam CT (CBCT) imaging. RO beads were contoured using automated thresholding, and feasibility of matching between the simulated radiotherapy planning dataset (AVE-IP image from 4D data) and CBCT scans assessed. Additional kV, MV, helical CT and CBCT images of RO beads were obtained using an in-house phantom. Stability of RO bead position was assessed by comparing 4D-CT imaging to CT scans taken 6–20 days following TACE.Results:Eight patients were treated and 4D-CT and CBCT images acquired. RO beads were visible on 4D-CT and CBCT images in all cases and matching successfully performed. Differences in centre of mass of RO beads between CBCT and simulated radiotherapy planning scans (AVE-IP dataset) were 2.0 mm mediolaterally, 1.7 mm anteroposteriorally and 3.5 mm craniocaudally. RO beads in the phantom were visible on all imaging modalities assessed. RO bead position remained stable up to 29 days post TACE.Conclusion:RO beads are visible on IGRT imaging modalities, showing minimal artefact. They can be used for on-set matching with CBCT and remain stable over time.Advances in knowledge:The role of RO beads as fiducial markers for stereotactic liver radiotherapy is feasible and warrants further exploration as a combination therapy approach.

01 Oct 2021·Anti-Cancer DrugsQ4 · MEDICINE

Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia

Q4 · MEDICINE

Article

Author: Lewis, Andrew L. ; Lloyd, Andrew W. ; Hagan, Alice E. ; Westhorpe, Adam ; Sharma, Ricky A. ; Phillips, Gary J. ; Carter, Rebecca ; Macfarlane, Wendy M. ; Znati, Sami A.

Vandetanib-eluting radiopaque beads (VERB) have been developed for use in transarterial chemoembolization of liver tumours, with the goal of combining embolization with local delivery of antiangiogenic therapy. The objective of this study was to investigate how embolization-induced hypoxia may affect antitumoural activity of vandetanib, an inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), in the context of hepatocellular carcinoma (HCC) treatment. We studied the effect of vandetanib on proliferation, cell cycle and apoptosis of HCC cells, in hypoxic conditions, as well as the direct effects of the beads on 3D HCC spheroids. Vandetanib suppressed proliferation and induced apoptosis of HCC cells in vitro and was equipotent in hypoxic and normoxic conditions. High degrees of apoptosis were observed among cell lines in which vandetanib suppressed ERK1/2 phosphorylation and upregulated the proapoptotic protein Bim, but this did not appear essential for vandetanib-induced cell death in all cell lines. Vandetanib also suppressed the hypoxia-induced secretion of VEGF from HCC cells and inhibited proliferation of endothelial cells. Incubation of tumour spheroids with VERB led to sustained growth inhibition equivalent to the effect of free drug. We conclude that vandetanib has both antiangiogenic and direct anticancer activity against HCC cells even in hypoxic conditions, warranting the further evaluation of VERB as novel anticancer agents.

100 Deals associated with Biocompatibles UK Ltd.

100 Translational Medicine associated with Biocompatibles UK Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Yttrium 90	-	Phase 3

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis